Trials / Completed
CompletedNCT01652144
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- NCIC Clinical Trials Group · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out what effects a new drug AT7519M has on mantle cell lymphoma.
Detailed description
This research is being done because AT7519M has been shown to shrink tumours in animals and has been studied in a few people and seems promising but it is not clear if it can offer better results than standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT7519M |
Timeline
- Start date
- 2012-09-14
- Primary completion
- 2014-12-02
- Completion
- 2015-02-13
- First posted
- 2012-07-27
- Last updated
- 2023-08-04
Locations
6 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01652144. Inclusion in this directory is not an endorsement.